BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 18380382)

  • 1. [The value of positron emission tomography in the diagnosis and treatment of oesophageal cancer].
    Omloo JM; Westerterp M; Sloof GW; Hoekstra OS; van Lanschot JJ
    Ned Tijdschr Geneeskd; 2008 Feb; 152(7):365-70. PubMed ID: 18380382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can ¹⁸F-fluorodeoxyglucose positron emission tomography predict responses to neoadjuvant therapy in oesophageal cancer patients? A meta-analysis.
    Chen YM; Pan XF; Tong LJ; Shi YP; Chen T
    Nucl Med Commun; 2011 Nov; 32(11):1005-10. PubMed ID: 21886014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of positron emission tomography in the (re-)staging of oesophageal cancer.
    Westerterp M; Van Westreenen HL; Sloof GW; Plukker JT; Van Lanschot JJ
    Scand J Gastroenterol Suppl; 2006; (243):116-22. PubMed ID: 16782630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response monitoring of neoadjuvant therapy using CT, EUS, and FDG-PET.
    Sloof GW
    Best Pract Res Clin Gastroenterol; 2006; 20(5):941-57. PubMed ID: 16997171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET.
    Westerterp M; Omloo JM; Sloof GW; Hulshof MC; Hoekstra OS; Crezee H; Boellaard R; Vervenne WL; ten Kate FJ; van Lanschot JJ
    Int J Hyperthermia; 2006 Mar; 22(2):149-60. PubMed ID: 16754598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomography for monitoring response to neoadjuvant therapy in patients with oesophageal and gastro-oesophageal junction carcinoma.
    Suttie SA; Welch AE; Park KG
    Eur J Surg Oncol; 2009 Oct; 35(10):1019-29. PubMed ID: 19232881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy--systematic review.
    Westerterp M; van Westreenen HL; Reitsma JB; Hoekstra OS; Stoker J; Fockens P; Jager PL; Van Eck-Smit BL; Plukker JT; van Lanschot JJ; Sloof GW
    Radiology; 2005 Sep; 236(3):841-51. PubMed ID: 16118165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy.
    Cerfolio RJ; Bryant AS; Ohja B; Bartolucci AA; Eloubeidi MA
    J Thorac Cardiovasc Surg; 2005 Jun; 129(6):1232-41. PubMed ID: 15942562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited additional value of positron emission tomography in staging oesophageal cancer.
    van Westreenen HL; Westerterp M; Sloof GW; Groen H; Bossuyt PM; Jager PL; Comans EF; van Dullemen HM; Fockens P; Stoker J; van der Jagt EJ; van Lanschot JJ; Plukker JT
    Br J Surg; 2007 Dec; 94(12):1515-20. PubMed ID: 17902092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [18F-FDG-PET in therapy response of esophageal cancer].
    Wieder HA; Herrmann K; Ott K; Krause BJ
    Radiologe; 2007 Feb; 47(2):110-4. PubMed ID: 17225182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorine-18 fluorodeoxyglucose positron emission tomography in the preoperative staging of thoracic oesophageal and gastro-oesophageal junction cancer: a prospective study.
    Katsoulis IE; Wong WL; Mattheou AK; Damani N; Chambers J; Livingstone JI
    Int J Surg; 2007 Dec; 5(6):399-403. PubMed ID: 17631431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of response to neoadjuvant therapy in esophageal cancer: an updated systematic review of diagnostic accuracy of endoscopic ultrasonography and fluorodeoxyglucose positron emission tomography.
    Ngamruengphong S; Sharma VK; Nguyen B; Das A
    Dis Esophagus; 2010 Apr; 23(3):216-31. PubMed ID: 19515185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma.
    Kato H; Miyazaki T; Nakajima M; Takita J; Kimura H; Faried A; Sohda M; Fukai Y; Masuda N; Fukuchi M; Manda R; Ojima H; Tsukada K; Kuwano H; Oriuchi N; Endo K
    Cancer; 2005 Jan; 103(1):148-56. PubMed ID: 15558794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of fluorodeoxyglucose PET on the management of esophageal cancer.
    Salavati A; Basu S; Heidari P; Alavi A
    Nucl Med Commun; 2009 Feb; 30(2):95-116. PubMed ID: 19194210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The value of positron emission tomography in the diagnosis and treatment of oesophageal cancer].
    Balink H; Gemmel FA; van Schelven WD
    Ned Tijdschr Geneeskd; 2008 May; 152(20):1177-8; author reply 1178. PubMed ID: 18549145
    [No Abstract]   [Full Text] [Related]  

  • 16. The added value of metabolic imaging with FDG-PET in oesophageal cancer: prognostic role and prediction of response to treatment.
    Bombardieri E
    Eur J Nucl Med Mol Imaging; 2006 Jul; 33(7):753-8. PubMed ID: 16733687
    [No Abstract]   [Full Text] [Related]  

  • 17. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
    Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomography in the staging of esophageal cancer.
    Leccisotti L
    Rays; 2006; 31(1):9-12. PubMed ID: 16999368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incremental value of 18F-FDG PET/CT in therapeutic decision-making of potentially curable esophageal adenocarcinoma.
    Purandare NC; Pramesh CS; Karimundackal G; Jiwnani S; Agrawal A; Shah S; Kulkarni M; Laskar SG; Rangarajan V
    Nucl Med Commun; 2014 Aug; 35(8):864-9. PubMed ID: 24751701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma.
    Bastiaannet E; Uyl-de Groot CA; Brouwers AH; van der Jagt EJ; Hoekstra OS; Oyen W; Verzijlbergen F; van Ooijen B; Thompson JF; Hoekstra HJ
    Ann Surg; 2012 Apr; 255(4):771-6. PubMed ID: 22367443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.